Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer (including some brain/spinal tumors) with ALK, ROS1, or NTRK gene rearrangement found by the study’s approved test.
- You can take pills by swallowing the capsules whole (no chewing, crushing, or opening).
- You have at least one measurable tumor spot on scans (a measurable brain-only spot is allowed in some cases).
- You are generally well enough for treatment (ECOG performance status 0–1) and are at least age 18 for Phase 1 (or age 20 if required locally).
- Your blood tests and organ function are within required safety ranges (for example, white blood cells, platelets, kidney function, and liver tests).
- Your body has recovered from prior cancer treatment side effects (other than hair loss) to mild or none (grade 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Hear when a new Locally Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.